» Articles » PMID: 36822173

Mapping the Interplay Between NK Cells and HIV: Therapeutic Implications

Overview
Journal J Leukoc Biol
Date 2023 Feb 23
PMID 36822173
Authors
Affiliations
Soon will be listed here.
Abstract

Although highly effective at durably suppressing plasma HIV-1 viremia, combination antiretroviral therapy (ART) treatment regimens do not eradicate the virus, which persists in long-lived CD4+ T cells. This latent viral reservoir serves as a source of plasma viral rebound following treatment interruption, thus requiring lifelong adherence to ART. Additionally, challenges remain related not only to access to therapy but also to a higher prevalence of comorbidities with an inflammatory etiology in treated HIV-1+ individuals, underscoring the need to explore therapeutic alternatives that achieve sustained virologic remission in the absence of ART. Natural killer (NK) cells are uniquely positioned to positively impact antiviral immunity, in part due to the pleiotropic nature of their effector functions, including the acquisition of memory-like features, and, therefore, hold great promise for transforming HIV-1 therapeutic modalities. In addition to defining the ability of NK cells to contribute to HIV-1 control, this review provides a basic immunologic understanding of the impact of HIV-1 infection and ART on the phenotypic and functional character of NK cells. We further delineate the qualities of "memory" NK cell populations, as well as the impact of HCMV on their induction and subsequent expansion in HIV-1 infection. We conclude by highlighting promising avenues for optimizing NK cell responses to improve HIV-1 control and effect a functional cure, including blockade of inhibitory NK receptors, TLR agonists to promote latency reversal and NK cell activation, CAR NK cells, BiKEs/TriKEs, and the role of HIV-1-specific bNAbs in NK cell-mediated ADCC activity against HIV-1-infected cells.

Citing Articles

Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1-infected CD4+ T cells by ADCC.

Tomescu C, Ochoa-Ortiz A, Lu L, Kong H, Riley J, Montaner L J Immunol. 2025; 214(2):253-264.

PMID: 40073240 PMC: 11878998. DOI: 10.1093/jimmun/vkae028.


Emerging role of natural killer cells in non-AIDS comorbidities during suppressive antiretroviral therapy.

Alles M, Demberg T, Liyanage N Curr Opin HIV AIDS. 2025; 20(2):145-153.

PMID: 39774039 PMC: 11802316. DOI: 10.1097/COH.0000000000000913.


Emerging Insights into Memory Natural Killer Cells and Clinical Applications.

Kokici J, Preechanukul A, Arellano-Ballestero H, Gorou F, Peppa D Viruses. 2024; 16(11).

PMID: 39599860 PMC: 11599065. DOI: 10.3390/v16111746.


Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing.

de Taeye S, Schriek A, Umotoy J, Grobben M, Burger J, Sanders R Commun Biol. 2024; 7(1):964.

PMID: 39122901 PMC: 11316088. DOI: 10.1038/s42003-024-06659-8.


Persistence of a Skewed Repertoire of NK Cells in People with HIV-1 on Long-Term Antiretroviral Therapy.

Anderko R, DePuyt A, Bronson R, Bullotta A, Aga E, Bosch R J Immunol. 2024; 212(10):1564-1578.

PMID: 38551350 PMC: 11073922. DOI: 10.4049/jimmunol.2300672.


References
1.
Gondois-Rey F, Cheret A, Granjeaud S, Mallet F, Bidaut G, Lecuroux C . NKG2C memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147. Clin Transl Immunology. 2017; 6(7):e150. PMC: 5539415. DOI: 10.1038/cti.2017.22. View

2.
Neelapu S, Tummala S, Kebriaei P, Wierda W, Locke F, Lin Y . Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018; 15(4):218. PMC: 6716606. DOI: 10.1038/nrclinonc.2018.20. View

3.
Schmidt M, Hagner N, Marco A, Konig-Merediz S, Schroff M, Wittig B . Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703. Nucleic Acid Ther. 2015; 25(3):130-40. PMC: 4440985. DOI: 10.1089/nat.2015.0533. View

4.
Bullen C, Laird G, Durand C, Siliciano J, Siliciano R . New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014; 20(4):425-9. PMC: 3981911. DOI: 10.1038/nm.3489. View

5.
Della Chiesa M, Pesce S, Muccio L, Carlomagno S, Sivori S, Moretta A . Features of Memory-Like and PD-1(+) Human NK Cell Subsets. Front Immunol. 2016; 7:351. PMC: 5021715. DOI: 10.3389/fimmu.2016.00351. View